Search
- Page Path
-
HOME
> Search
Case Reports
- Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event
-
Dae-ha Kim, Minkoo Kim, Hyung Joon Yim, Sang Jun Suh, Young Kul Jung
-
J Liver Cancer. 2019;19(2):154-158. Published online September 30, 2019
-
DOI: https://doi.org/10.17998/jlc.19.2.154
-
-
Abstract
PDF
- A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved.
- Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
-
Dae-ha Kim, Gee ho Min, Dong-won Lee, Ke Ryun Ahn, Ji Hye Kim, Snag-Jun Suh, Young Kul Jung, Hyung Joon Yim
-
J Liver Cancer. 2016;16(1):57-62. Published online March 31, 2016
-
DOI: https://doi.org/10.17998/jlc.16.1.57
-
-
Abstract
PDF
- Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the
vascular endothelial growth factor receptor intracellular kinase pathway and is the first
agent to demonstrate a statistically significant improvement in overall survival for patients
with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or
complete response reported in the previous studies. We herein report a case of dramatic
partial response in a patient who had advanced HCC with multiple lung metastasis and portal
vein thrombosis treated with sorafenib.
TOP